Design and Development of Novel Transdermal Nanoemulgel for Alzheimer’s Disease: Pharmacokinetic, Pharmacodynamic and Biochemical Investigations

Author(s): Sonal Setya, Tushar Madaan, Bal Kishen Razdan, Mamta Farswan, Sushama Talegaonkar*.

Journal Name: Current Drug Delivery

Volume 16 , Issue 10 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Alzheimer’s disease is a chronic progressive neurodegenerative disorder associated with depletion of acetylcholine. Oral treatment with tacrine hydrochloride; a reversible inhibitor of acetylcholinesterase, finds limited use in Alzheimer’s disease due to frequent dosing, hepatotoxicity and extensive pre-systemic metabolism.

Objectives: The objective of the study was to evaluate pharmacokinetic, pharmacodynamic, safety and stability profile of transdermal w/o nanoemulsion gel of tacrine hydrochloride and determine its relative bioavailability from transdermal nanogel in contrast to marketed capsule and conventional hydrogel.

Methods: The optimized nanoemulsion gel NEGT4 (droplet size 156.4 ±0.48 nm, with poly dispersity index 0.36 ±0.4, permeation flux 6.172±2.94 µg/cm2/h across rat skin) was prepared by spontaneous emulsification followed by sonication. NEGT4 contained 7 mg of drug in 10% w/w distilled water, 30% w/w surfactant (Labrafil M) and cosurfactant (Transcutol P) mixture in ratio 1:4 and 60 % Capryol 90 as oily phase thickened with 98.9 mg ethyl cellulose (20 cps). In vivo studies were carried out on male Wistar rats following standard guidelines. Scopolamine was used to induce amnesia in rats which is a characteristic of Alzheimer’s disease. Various formulations were compared by performing pharmacokinetic, histopathological, behavioural and biochemical studies on rats. Stability studies on nanoemulsion gels were carried out in accordance with The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines.

Results: Pharmacokinetic studies exhibited significantly greater extent of absorption from NEGT4 in comparison to capsule and hydrogel with a 2.18 and 5.26-fold increase respectively. Significant improvement in neurobehavioral parameters was observed with NEGT4 in scopolamine-induced amnesic rats. Biochemical assessment showed superior anti-amnesic activity of NEGT4 through augmentation of antioxidant enzymes, decreased lipid peroxidation and acetylcholinesterase activity. Low value of serum aminotransferase in rats treated with NEGT4 indicated the absence of hepatotoxicity. NEGT4 was found to be non-irritant and possessed a shelf life of 4.11 years.

Conclusion: Developed nanoemulsion gel of tacrine hydrochloride was found to be safe, stable, and efficacious and has immense potential to be used in the therapy of Alzheimer’s disease.

Keywords: Nanoemulsion, tacrine hydrochloride, bioavailability, in vivo, histological, shelf life.

[1]
Brookmeyer, R.; Johnson, E.; Ziegler-Graham, K.; Arrighi, H.M. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement., 2007, 3(3), 186-191.
[http://dx.doi.org/10.1016/j.jalz.2007.04.381] [PMID: 19595937]
[2]
Alzheimer Association. Alzheimer’s Disease Facts and Figures. Alzheimers Dement., 2016, 12, 1-80 Available from.alz.org/facts%5Cnhttp://www.alz.org/facts/overview.asp#quickFacts
[3]
McGleenon, B.M.; Dynan, K.B.; Passmore, A.P. Acetylcholinesterase inhibitors in Alzheimer’s disease. Br. J. Clin. Pharmacol., 1999, 48(4), 471-480.
[http://dx.doi.org/10.1046/j.1365-2125.1999.00026.x] [PMID: 10583015]
[4]
Crismon, M.L. Tacrine: First drug approved for Alzheimer’s disease. Ann. Pharmacother., 1994, 28(6), 744-751.
[http://dx.doi.org/10.1177/106002809402800612] [PMID: 7919566]
[5]
Madden, S.; Spaldin, V.; Park, B.K. Clinical pharmacokinetics of tacrine. Clin. Pharmacokinet., 1995, 28(6), 449-457.
[http://dx.doi.org/10.2165/00003088-199528060-00003] [PMID: 7656503]
[6]
Wagstaff, A.J.; McTavish, D. Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer’s disease. Drugs Aging, 1994, 4(6), 510-540.
[http://dx.doi.org/10.2165/00002512-199404060-00006] [PMID: 7521234]
[7]
Shaikh, J.; Ankola, D.D.; Beniwal, V.; Singh, D.; Kumar, M.N. Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur. J. Pharm. Sci., 2009, 37(3-4), 223-230.
[http://dx.doi.org/10.1016/j.ejps.2009.02.019] [PMID: 19491009]
[8]
Sutthanut, K.; Lu, X.; Jay, M.; Sripanidkulchai, B. Solid lipid nanoparticles for topical administration of Kaempferia parviflora extracts. J. Biomed. Nanotechnol., 2009, 5(2), 224-232.
[http://dx.doi.org/10.1166/jbn.2009.1026] [PMID: 20055101]
[9]
Talegaonkar, S.; Tariq, M.; Alabood, R.M. Design and development of o/w nanoemulsion for the transdermal delivery of ondansetron. Bull. Pharm. Res., 2011, 1, 18-30.
[10]
Meng, S.; Chen, Z.; Yang, L.; Zhang, W.; Liu, D.; Guo, J.; Guan, Y.; Li, J. Enhanced transdermal bioavailability of testosterone propionate via surfactant-modified ethosomes. Int. J. Nanomedicine, 2013, 8, 3051-3060.
[http://dx.doi.org/10.2147/IJN.S46748] [PMID: 23990718]
[11]
Hosny, K.M.; Aldawsari, H.M. Avanafil liposomes as transdermal drug delivery for erectile dysfunction treatment: Preparation, characterization, and in vitro, ex vivo and in vivo studies. Trop. J. Pharm. Res., 2015, 14, 559-565.
[http://dx.doi.org/10.4314/tjpr.v14i4.1]
[12]
Madikattu, K.; Kalamata, V.; Srisailam, K. Enhanced bioavailability of glimepiride through microemulsion based transdermal gels. Int. J. Pharm. Sci. Res., 2016, 7, 5052-5055.
[http://dx.doi.org/10.13040/IJPSR.0975-8232.7(12).5052-55]
[13]
Asthana, G.S.; Sharma, P.K.; Asthana, A. In vitro and in vivo evaluation of niosomal formulation for controlled delivery of clarithromycin. Scientifica (Cairo), 2016, 20166492953
[http://dx.doi.org/10.1155/2016/6492953] [PMID: 27293976]
[14]
Setya, S.; Talegaonkar, S.; Razdan, B.K. Nanoemulsions: Formulation methods and stability aspects. World J. Pharm. Pharm. Sci., 2014, 3, 2214-2228.
[15]
Setya, S.; Negi, P.; Razdan, B.K. Design, development and in vitro investigation of water in oil nanoemulsion for transdermal delivery. World J. Pharm. Pharm. Sci., 2014, 3, 1495-1512.
[16]
Sathyan, G.; Ritschel, W.A.; Hussain, A.S. Transdermal delivery of tacrine: I. Identification of a suitable delivery vehicle. Int. J. Pharm., 1995, 114, 75-83.
[http://dx.doi.org/10.1016/0378-5173(94)00214-P]
[17]
Goverdhan, P.; Sravanthi, A.; Mamatha, T. Neuroprotective effects of Meloxicam and Selegiline in scopolamine-induced cognitive impairment and oxidative stress. Int. J. Alzheimers Dis., 2012, 2012974013
[http://dx.doi.org/10.1155/2012/974013] [PMID: 22536538]
[18]
Singh, M.; Singh, V.; Veermaram, S. Memory enhancing effect of mirtazapine and ascorbic acid on scopolamine induced amnesia in rats. Guru Drone J. Pharm. Res., 2013, 1, 29-38.
[http://dx.doi.org/www.gdjpr.com/pdf/Memory-Enhancing-Effect-of-Mirtazapine-with-Ascorbic-acid-on-Scopolamine-Induced-Amnesia-in Rats-Mamta-Farswan-Singh-Vinod-Singh-Veermaram-Shalini-Rawal-Himani-Bajaj-Anupam-Bisht.pdf]
[19]
Itoh, J.; Nabeshima, T.; Kameyama, T. Utility of an elevated plus-maze for dissociation of amnesic and behavioral effects of drugs in mice. Eur. J. Pharmacol., 1991, 194(1), 71-76.
[http://dx.doi.org/10.1016/0014-2999(91)90125-A] [PMID: 2060594]
[20]
Morris, R. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods, 1984, 11(1), 47-60.
[http://dx.doi.org/10.1016/0165-0270(84)90007-4] [PMID: 6471907]
[21]
Ellman, G.L.; Courtney, K.D.; Andres, V., Jr; Feather-Stone, R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol., 1961, 7, 88-95.
[http://dx.doi.org/10.1016/0006-2952(61)90145-9] [PMID: 13726518]
[22]
Lucky, H. Catalase.Method Enzym. Anal; Bergmeyer, H., Ed.; Academic Press: New York, London, 1965, pp. 885-894.
[http://dx.doi.org/10.1016/B978-0-12-395630-9.50158-4]
[23]
Reitman, S.; Frankel, S. A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases. Am. J. Clin. Pathol., 1957, 28(1), 56-63.
[http://dx.doi.org/10.1093/ajcp/28.1.56] [PMID: 13458125]
[24]
Azeem, A.; Talegaonkar, S.; Negi, L.M.; Ahmad, F.J.; Khar, R.K.; Iqbal, Z. Oil based nanocarrier system for transdermal delivery of ropinirole: A mechanistic, pharmacokinetic and biochemical investigation. Int. J. Pharm., 2012, 422(1-2), 436-444.
[http://dx.doi.org/10.1016/j.ijpharm.2011.10.039] [PMID: 22057087]
[25]
Ali, M.S.; Alam, M.S.; Alam, N.; Siddiqui, M.R. Preparation, characterization and stability study of dutasteride loaded nanoemulsion for treatment of benign prostatic hypertrophy. Iran. J. Pharm. Res., 2014, 13(4), 1125-1140.
[http://dx.doi.org/www.ncbi.nlm.nih.gov/pmc/articles/PMC4232777] [PMID: 25587300]
[26]
Shafiq, S.; Shakeel, F.; Khar, R.K. Enhanced stability of ramipril in nanoemulsion containing cremophor-EL: A technical note. AAPS PharmSciTech, 2008, 9(4), 1097-1101.http://www.springerlink.com/index/10.1208/s12249-008-9151-918
[http://dx.doi.org/10.1208/s12249-008-9151-8] [PMID: 18958628]
[27]
Shakeel, F.; Baboota, S.; Ahuja, A. Stability evaluation of celecoxib nanoemulsion containing Tween 80. Thaiphesatchasan, 2008, 32, 4-9.
[28]
Setya, S.; Razdan, B.; Talegaonkar, S. Development and validation of Rp-Hplc method for determination of saxagliptin hydrochloride in bulk. J. Adv. Pharm. Educ. Res., 2014, 4, 435-439.
[29]
Marisco, P.C.; Carvalho, F.B.; Rosa, M.M.; Girardi, B.A.; Gutierres, J.M.; Jaques, J.A.; Salla, A.P.; Pimentel, V.C.; Schetinger, M.R.; Leal, D.B.; Mello, C.F.; Rubin, M.A. Piracetam prevents scopolamine-induced memory impairment and decrease of NTPDase, 5′-nucleotidase and adenosine deaminase activities. Neurochem. Res., 2013, 38(8), 1704-1714.
[http://dx.doi.org/10.1007/s11064-013-1072-6] [PMID: 23677777]
[30]
Mann, H.; McCoy, M.T.; Subramaniam, J.; Van Remmen, H.; Cadet, J.L. Overexpression of superoxide dismutase and catalase in immortalized neural cells: Toxic effects of hydrogen peroxide. Brain Res., 1997, 770(1-2), 163-168.
[http://dx.doi.org/10.1016/S0006-8993(97)00768-3] [PMID: 9372215]
[31]
Grotto, D.; Maria, L.S.; Valentini, J. Importance of the lipid peroxidation biomarkers and methodological aspects FOR malondialdehyde quantification. Quim. Nova, 2009, 32, 169-174.
[http://dx.doi.org/10.1590/S0100-40422009000100032]
[32]
Balson, R.; Gibson, P.; Ames, D. Tacrine-induced hepatotoxicity. CNS Drugs, 1995, 4, 168-181.
[http://dx.doi.org/10.2165/00023210-199504030-00002]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 16
ISSUE: 10
Year: 2019
Page: [902 - 912]
Pages: 11
DOI: 10.2174/1567201816666191022105036
Price: $65

Article Metrics

PDF: 21

Special-new-year-discount